Assignee
XOMA TECHNOLOGY LTD
US·49 granted patents·20 pending applications·573 citations·filing 1995–2023
Top patents by PatentIndex Score
69 records- 0197US7531166B2IL-1β binding antibodies and fragments thereofXOMA TECHNOLOGY LTD·Filed 2006·Granted May 12, 2009·49 cites·10 claims
- 0296US7744865B2IL1-β Binding antibodies and fragments thereofXOMA TECHNOLOGY LTD·Filed 2009·Granted Jun 29, 2010·23 cites·10 claims
- 0396US7582742B2Method of treating or preventing an IL-1 related disease or conditionXOMA TECHNOLOGY LTD·Filed 2008·Granted Sep 1, 2009·23 cites·12 claims
- 0495US7829093B2Method of treating an IL-1 related autoimmune disease or conditionXOMA TECHNOLOGY LTD·Filed 2009·Granted Nov 9, 2010·21 cites·6 claims
- 0595US7695717B2Method of treating an IL-1 related inflammatory disease or conditionXOMA TECHNOLOGY LTD·Filed 2008·Granted Apr 13, 2010·21 cites·22 claims
- 0693US7829094B2Method of treating an IL-1 related cancerXOMA TECHNOLOGY LTD·Filed 2009·Granted Nov 9, 2010·13 cites·12 claims
- 0793US7744866B2IL-1β binding antibodies and binding fragments thereofXOMA TECHNOLOGY LTD·Filed 2009·Granted Jun 29, 2010·12 cites·10 claims
- 0893US7695718B2Methods for the treatment of IL-1β related diseasesXOMA TECHNOLOGY LTD·Filed 2007·Granted Apr 13, 2010·19 cites·54 claims
- 0992US8584349B2Flexible manufacturing systemXOMA TECHNOLOGY LTD·Filed 2012·Granted Nov 19, 2013·41 cites·28 claims
- 1092US7943121B2IL-1β binding antibodies and fragments thereofXOMA TECHNOLOGY LTD·Filed 2009·Granted May 17, 2011·11 cites·10 claims
- 1192US7094579B2Eukaryotic signal sequences for prokaryotic expressionXOMA TECHNOLOGY LTD·Filed 2002·Granted Aug 22, 2006·24 cites·12 claims
- 1291US6376217B1Fusion proteins and polynucleotides encoding gelonin sequencesXOMA TECHNOLOGY LTD·Filed 2000·Granted Apr 23, 2002·18 cites·15 claims
- 1390US7988968B2Method of treating an IL-1 related coronary conditionXOMA TECHNOLOGY LTD·Filed 2009·Granted Aug 2, 2011·7 cites·12 claims
- 1489US9944698B2ModulatorsXOMA TECHNOLOGY LTD·Filed 2014·Granted Apr 17, 2018·5 cites·17 claims
- 1589US7192737B2Methods and materials for increasing expression of recombinant polypeptidesXOMA TECHNOLOGY LTD·Filed 2003·Granted Mar 20, 2007·13 cites·71 claims
- 1689US6376211B1Agents and methods for inhibiting F1/F0 ATPaseXOMA TECHNOLOGY LTD·Filed 2000·Granted Apr 23, 2002·38 cites·22 claims
- 1788US9206252B2Pharmaceutical compositions comprising IL-1B binding antibodies and fragments thereofXOMA TECHNOLOGY LTD·Filed 2013·Granted Dec 8, 2015·5 cites·13 claims
- 1888US8377442B2Method of treating inflammatory eye disease with IL-1β binding antibodiesXOMA TECHNOLOGY LTD·Filed 2011·Granted Feb 19, 2013·6 cites·10 claims
- 1988US7977068B2Eukaryotic signal sequences for polypeptide expression and polypeptide display librariesXOMA TECHNOLOGY LTD·Filed 2008·Granted Jul 12, 2011·6 cites·12 claims
- 2088US6495516B1Method for killing gram-negative bacteria with biologically active peptides from functional domains of bacterial/permeability-increasing proteinXOMA TECHNOLOGY LTD·Filed 2001·Granted Dec 17, 2002·20 cites·10 claims
- 2187US9145458B2Antibodies specific for TGF-β and methods of treatment thereofXOMA TECHNOLOGY LTD·Filed 2013·Granted Sep 29, 2015·7 cites·24 claims
- 2287US7972811B2Eukaryotic signal sequences for polypeptide expression and polypeptide display librariesXOMA TECHNOLOGY LTD·Filed 2008·Granted Jul 5, 2011·5 cites·12 claims
- 2387US7396661B2Eukaryotic signal sequences for polypeptide expression and polypeptide display librariesXOMA TECHNOLOGY LTD·Filed 2003·Granted Jul 8, 2008·10 cites·12 claims
- 2486US9714285B2TGF-beta-specific antibodies and methods of use thereof for treatmentXOMA TECHNOLOGY LTD·Filed 2015·Granted Jul 25, 2017·4 cites·20 claims
- 2585US7749731B2Methods for recombinant peptide productionXOMA TECHNOLOGY LTD·Filed 2007·Granted Jul 6, 2010·5 cites·21 claims
- 2685US6803210B2Methods and cells for expression of recombinant protein products under the transcriptional control of an inducible promoterXOMA TECHNOLOGY LTD·Filed 2001·Granted Oct 12, 2004·11 cites·28 claims
- 2785US6649742B1Immunotoxins comprising ribosome-inactivating proteinsXOMA TECHNOLOGY LTD·Filed 2000·Granted Nov 18, 2003·37 cites·20 claims
- 2885US6500648B1Methods for recombinant peptide productionXOMA TECHNOLOGY LTD·Filed 2001·Granted Dec 31, 2002·10 cites·19 claims
- 2984US8377429B2Methods for improvement of beta cell function with anti-IL-1β antibodies or fragments thereofXOMA TECHNOLOGY LTD·Filed 2009·Granted Feb 19, 2013·5 cites·27 claims
- 3082US10358486B2Nucleic acids encoding, and methods of producing, antibodies specific for transforming growth factor (TGF)-βXOMA TECHNOLOGY LTD·Filed 2017·Granted Jul 23, 2019·2 cites·20 claims
- 3182US10167334B2Treatment of cancer using anti-TGF-BETA and PD-1 antibodiesXOMA TECHNOLOGY LTD·Filed 2016·Granted Jan 1, 2019·4 cites·15 claims
- 3281US7247454B2Methods for recombinant peptide productionXOMA TECHNOLOGY LTD·Filed 2002·Granted Jul 24, 2007·6 cites·21 claims
- 3381US6436660B1Identification of novel antimicrobial agents using metabolic oxidation-reduction indicator dyesXOMA TECHNOLOGY LTD·Filed 2000·Granted Aug 20, 2002·7 cites·8 claims
- 3480US7993915B2Methods and materials for increasing expression of recombinant polypeptidesXOMA TECHNOLOGY LTD·Filed 2007·Granted Aug 9, 2011·2 cites·50 claims
- 3579US6906037B2Therapeutic peptide-based constructsXOMA TECHNOLOGY LTD·Filed 2003·Granted Jun 14, 2005·5 cites·16 claims
- 3678US12071475B2Antibodies that bind transforming growth factor beta (TGF beta) and methods of use thereof for treatmentXOMA TECHNOLOGY LTD·Filed 2021·Granted Aug 27, 2024·0 cites·19 claims
- 3778US2023416354A1Treatment of cancer using inhibitors of tgf-beta and pd-1XOMA TECHNOLOGY LTD·Filed 2023·Application pending·0 cites
- 3876US6376465B1Therapeutic uses of BPI protein products in BPI-deficient humansXOMA TECHNOLOGY LTD·Filed 2000·Granted Apr 23, 2002·5 cites·9 claims
- 3974US10683347B2Treatment of cancer using anti-TGF-β and anti-PD-1 antibodiesXOMA TECHNOLOGY LTD·Filed 2018·Granted Jun 16, 2020·1 cites·16 claims
- 4074US7794976B2Methods and materials for expression of a recombinant proteinXOMA TECHNOLOGY LTD·Filed 2007·Granted Sep 14, 2010·3 cites·36 claims
- 4171US11098111B2Method of treating cancer by administering an antibody that binds transforming growth factor beta (TGF-beta) 1, TGF-beta 2 and TGF-beta 3XOMA TECHNOLOGY LTD·Filed 2019·Granted Aug 24, 2021·0 cites·24 claims
- 4271US6964948B2Therapeutic peptide-based constructs derived from Domain II of bactericidal/permeability-increasing proteinXOMA TECHNOLOGY LTD·Filed 2002·Granted Nov 15, 2005·2 cites·61 claims
- 4368US11685775B2Method of increasing the ratio of effector T cells to regulatory T cells in a tumor by administering to a subject a TGF-beta inhibitor and a PD-1 antibodyXOMA TECHNOLOGY LTD·Filed 2020·Granted Jun 27, 2023·0 cites·16 claims
- 4465US2008145895A1Methods and Materials for Increasing Expression of Recombinant PolypeptidesXOMA TECHNOLOGY LTD·Filed 2007·Application pending·0 cites
- 4564US6455271B1Identification of novel antimicrobial agents using membrane potential indicator dyesXOMA TECHNOLOGY LTD·Filed 2000·Granted Sep 24, 2002·19 cites·11 claims
- 4660US6515104B1Therapeutic peptide-based constructs derived from domain II of bactericidal/permeability-increasing proteinXOMA TECHNOLOGY LTD·Filed 1999·Granted Feb 4, 2003·11 cites·7 claims
- 4760US6461824B1Production of chimeric antibodies with specificity to human tumor antigensXOMA TECHNOLOGY LTD·Filed 1995·Granted Oct 8, 2002·22 cites·198 claims
- 4859US2003166196A1Fusion proteins and polynucleotides encoding gelonin sequencesXOMA TECHNOLOGY LTD·Filed 2002·Application pending·0 cites
- 4958US2008241126A1Nucleic acids encoding Human Engineered heavy and light chain variable region sequences to Ep-CAMXOMA TECHNOLOGY LTD·Filed 2007·Application pending·0 cites
- 5057US7291451B2Modulation of pericyte proliferationXOMA TECHNOLOGY LTD·Filed 2004·Granted Nov 6, 2007·1 cites·2 claims
Showing the top 50 of 69 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →